Janwillem Naesens

Janwillem Naesens currently works at Cristal Delivery BV, as Director, OCTIMET Oncology NV, as Director, Highlight Therapeutics SL, as Director, Frontier Medicines Corp., as Director, Black Belt Therapeutics Ltd., as Director, DF II LP NV, as Director, and Droia Ventures, as Managing Partner from 2013.
Mr. Naesens also formerly worked at Convert Pharmaceuticals SA, as Chief Executive Officer & Director, NormOxys, Inc., as Director, Cyteir Therapeutics, Inc., as Independent Director from 2019 to 2022, Tusk Therapeutics Ltd., as Director, and Waterland Private Equity NV, as Investment Manager from 2011 to 2013.
Mr. Naesens received his graduate degree in 2005 from Katholieke Universiteit Leuven, undergraduate degree in 2004 from Télécom Paris, and Masters Business Admin degree in 2008 from INSEAD.